Compare iShares Core US Aggregate Bond ETF (AGG) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs Cytokinetics Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.98, while Cytokinetics Inc trades at $82.94 (market cap $11.62B). The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | CYTK | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $101.40 | $87.26 |
52-Week Low | $97.63 | $33.23 |
Market Cap | — | $11.62B |
Enterprise Value | — | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
